Skip to main content

Table 3 Baseline characteristics in the original and matched samples

From: Impact of hospital formulary intervention on carbapenem use: a segmented time-series analysis of consumption and a propensity score-matched non-inferiority study of treatment efficacy

 

Original

Matched

Before

After

SMD

Before

After

SMD

Confounders

115

 

146

  

97

 

97

  

 Age, mean (SD)

69.05

(11.44)

69.86

(13.16)

0.065

69.80

(11.24)

70.29

(11.02)

0.044

 Female, n (%)

35

(30.4)

52

(35.6)

0.110

31

(32.0)

29

(29.9)

0.045

 BMI, mean (SD)

21.21

(3.51)

21.93

(3.25)

0.214

21.47

(3.66)

21.37

(2.95)

0.030

 Cancer = TRUE, n (%)

88

(76.5)

91

(62.3)

0.020

73

(75.3)

70

(72.2)

0.070

 WBC, mean (SD)

10942.61

(7340.12)

9900.00

(4732.63)

0.169

9741.24

(4871.28)

9836.08

(4712.49)

0.020

 RBC, mean (SD)

386.36

(73.57)

380.65

(68.26)

0.080

381.08

(69.71)

383.70

(66.81)

0.038

 ALB, mean (SD)

3.25

(0.57)

3.38

(0.64)

0.214

3.28

(0.57)

3.33

(0.61)

0.098

 T-Bil, mean (SD)

2.08

(2.38)

2.31

(2.88)

0.088

2.13

(2.53)

2.23

(2.44)

0.041

 AST, mean (SD)

123.79

(177.89)

178.50

(410.06)

0.173

128.85

(184.36)

145.54

(318.37)

0.064

 ALT, mean (SD)

97.39

(117.97)

144.54

(244.91)

0.245

103.24

(124.09)

111.49

(150.15)

0.060

 ALP, mean (SD)

799.23

(695.59)

724.94

(634.41)

0.112

779.91

(654.17)

753.36

(635.46)

0.041

 LDH, mean (SD)

267.51

(154.25)

294.34

(279.35)

0.119

266.51

(155.67)

292.24

(260.42)

0.120

 γGTP, mean (SD)

321.40

(338.52)

311.88

(330.70)

0.028

313.35

(321.41)

310.53

(339.29)

0.009

 SCr, mean (SD)

0.88

(0.47)

0.86

(0.35)

0.059

0.88

(0.49)

0.89

(0.39)

0.004

 eGFR, mean (SD)

70.70

(23.24)

70.03

(23.60)

0.028

70.24

(21.95)

69.76

(25.12)

0.020

 CRP, mean (SD)

8.87

(7.55)

6.52

(7.23)

0.317

7.54

(6.93)

7.54

(7.95)

< 0.001

Cases using DRPM

9

1

 

7

1